<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707847</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx20180821</org_study_id>
    <nct_id>NCT03707847</nct_id>
  </id_info>
  <brief_title>Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL</brief_title>
  <official_title>Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the safety, tolerability and clinical effects of crizotinib combined with&#xD;
      etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT)&#xD;
      for patients with relapsed and refractory ALK-positive Anaplastic Large Cell Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, one-arm, multicenter clinical trial, aimed to evaluate the&#xD;
      safety, tolerability, and efficacy of crizotinib combined with etoposide followed by&#xD;
      autologous hematopoietic stem cell transplantation for relapsed and refractory ALK-positive&#xD;
      ALCL. A total of 20 patients are planned to be enrolled into the study. Patients with&#xD;
      diagnosis of relapsed and refractory ALK-positive ALCL will be treated with crizotinib plus&#xD;
      etoposide capsules followed by autologous hematopoietic stem cell transplantation. The&#xD;
      primary end points are objective responder rate (ORR) and progression free survival(PFS) and&#xD;
      the secondary end points include overall survival(OS) , and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Objective Responder Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>ALK-Positive Anaplastic Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Crizotinib + etoposide capsule+Auto-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.&#xD;
Crizotinib: 250mg, bis in die （BID）, PO.&#xD;
Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.&#xD;
Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>250mg, BID, PO</description>
    <arm_group_label>Crizotinib + etoposide capsule+Auto-HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide Capsule</intervention_name>
    <description>50mg, QD, PO, d1-10，21days for one cycle</description>
    <arm_group_label>Crizotinib + etoposide capsule+Auto-HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Auto-HSCT</intervention_name>
    <description>Auto-HSCT will be performed with patients who have achieved CR or VGPR.</description>
    <arm_group_label>Crizotinib + etoposide capsule+Auto-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria: Inclusion Criteria:&#xD;
&#xD;
          -  age:14-65 years;Eastern Cooperative Oncology Group (ECOG)score≤3;expected survival≥3&#xD;
             months&#xD;
&#xD;
          -  patients with ALK-positive Anaplastic Large Cell Lymphoma diagnosed by&#xD;
             immuno-histochemistry (IHC) or fluorescence in situ hybridization (FISH);&#xD;
&#xD;
          -  Refractory or relapse after at least 4 cycles of CHOP（cyclophosphamide,&#xD;
             hydroxydaunomycin, Oncovin, and prednisone）regimen&#xD;
&#xD;
          -  acceptable hematological indicators, no chemotherapy contraindications;&#xD;
&#xD;
          -  total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase&#xD;
             (ALT) ≤ 2.5 x upper age limit (ULN), if the abnormal laboratory parameters are&#xD;
             considered to be caused by lymphoma, patients Eligible conditions should be adjusted&#xD;
             to be incorporated into the group;&#xD;
&#xD;
          -  At least one measurable lesion by CT or PET-CT（Positron Emission Tomography-Computed&#xD;
             Tomography）;&#xD;
&#xD;
          -  exclude other major diseases, normal heart and lung function;&#xD;
&#xD;
          -  Female patients of childbearing age are negative for pregnancy test;&#xD;
&#xD;
          -  Cooperate with follow-up;&#xD;
&#xD;
          -  There are no other related treatments including traditional Chinese medicine,&#xD;
             immunotherapy, and biologic therapy (except for the treatment of anti-bone metastases&#xD;
             and other symptoms);&#xD;
&#xD;
          -  Signing informed consent *: Pathological histology must be consulted by a pathologist&#xD;
             at a provincial hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  rejecting providing blood preparation;&#xD;
&#xD;
          -  allergic to drug in this study and with metabolic block;&#xD;
&#xD;
          -  rejecting adopting reliable contraceptive method in pregnancy or lactation period;&#xD;
&#xD;
          -  uncontrolled internal medicine disease(including uncontrolled diabetes,severe&#xD;
             incompetence cardiac,lung,liver and pancreas）；&#xD;
&#xD;
          -  with severe infection;&#xD;
&#xD;
          -  with primary or secondary central nervous system tumor invasion;&#xD;
&#xD;
          -  with immunotherapy or radiotherapy contraindication;&#xD;
&#xD;
          -  ever suffered with malignant tumor;&#xD;
&#xD;
          -  having peripheral nervous system disorder or dysphrenia;&#xD;
&#xD;
          -  with no legal capacity,medical or ethical reasons affecting research proceeding;&#xD;
&#xD;
          -  participating other clinical trials simultaneously;&#xD;
&#xD;
          -  adopting other anti-tumor medicine excluding this research;&#xD;
&#xD;
          -  Patients with immunodeficiency, such as primary immunodeficiency syndrome or organ&#xD;
             transplant recipients&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients&#xD;
&#xD;
          -  the researchers considering it inappropriate to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi zhang, Pro,Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>crizotinib</keyword>
  <keyword>etoposide</keyword>
  <keyword>autologous hematopoietic stem cell transplantation</keyword>
  <keyword>ORR</keyword>
  <keyword>OS</keyword>
  <keyword>PFS</keyword>
  <keyword>adverse events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

